Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non‐neurogenic overactive bladder

Abstract

Due to the myriad of treatment options available and the potential increase in the number of patients afflicted with overactive bladder (OAB) who will require treatment, the Female Urology Special Advisory Group (FUSAG) of the Urological Society of Australia and New Zealand (USANZ), in conjunction with the Urogynaecological Society of Australasia (UGSA), see the need to move forward and set up management guidelines for physicians who may encounter or have a special interest in the treatment of this condition. These guidelines, by utilising and recommending evidence‐based data, will hopefully assist in the diagnosis, clinical assessment, and optimisation of treatment efficacy. They are divided into three sections: Diagnosis and Clinical Assessment, Conservative Management, and Surgical Management. These guidelines will also bring Australia and New Zealand in line with other regions of the world where guidelines have been established, such as the American Urological Association, European Association of Urology, International Consultation on Incontinence, and the National Institute for Health and Care Excellence guidelines of the UK.

Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB

“…Initial pharmacotherapy for OAB consists of either anticholinergics or mirabegron . Common adverse events of anticholinergics include dry mouth, and dry eyes, although without a negative impact on vaginal lubrication .…”

“…Initial pharmacotherapy for OAB consists of either anticholinergics or mirabegron. [9][10][11] Common adverse events of anticholinergics include dry mouth, and dry eyes, although without a negative impact on vaginal lubrication. 12 However, anticholinergic therapy has not consistently been shown to improve overall sexual function.…”

Is the development of clinical practice guidelines for non‐neurogenic overactive bladder trustworthy? A critical appraisal using the Appraisal of Guidelines, Research and Evaluation (AGREE) II instrument

“…After duplicates were eliminated and titles and abstracts were screened, we included seven CPGs: ‘Urinary incontinence in Women: management of urinary incontinence in women’, National Institute for Health and Care Excellence (NICE) ; ‘Diagnosis and Treatment of Overactive Bladder (non‐neurogenic) in Adults: AUA/SUFU guideline’, AUA/Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) ; ‘EAU Guidelines on Urinary Incontinence in Adults’, European Association of Urology (EAU) ; ‘Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non‐neurogenic overactive bladder’, USANZ/UGSA ; ‘CUA guideline on adult overactive bladder’, Canadian Urological Association (CUA) ; ‘Treatments for overactive bladder: focus on pharmacotherapy’, Society of Obstetricians and Gynaecologists of Canada (SOGC) ; and ‘Clinical guidelines for overactive bladder’, Japanese Urological Association (JUA) .…”

Position statement: a clinical approach to the management of adult non‐neurogenic overactive bladder

“…We conducted a MEDLINE literature search for English language original and review articles on non‐neurogenic OAB over the past 10 years. Published guidelines from international organisations 1 , 2 , 8 , 10 ‐ 14 were also included.…”